Tesla's Chip and European Breakthroughs Face a Demand Reality Check

Tesla shares rally ahead of earnings on AI5 chip progress and EU FSD approval, but U.S. demand concerns and analyst skepticism create a high-stakes backdrop for Q1 results.

Tesla shares have surged nearly 11% over the past week, fueled by a trio of positive developments. However, this rally sets a high bar for the company's quarterly earnings report due on Tuesday, April 22, against a backdrop of persistent concerns over U.S. demand and the financial weight of its ambitious projects.

The recent momentum stems from significant progress in Tesla's semiconductor and autonomous driving initiatives. CEO Elon Musk announced the completion of the design phase for the in-house AI5 chip, a milestone known as tape-out, sending shares up almost 8% on Wednesday. Musk touted the AI5 as potentially becoming one of the world's most-produced AI chips, with its successor, the AI6, already slated for design completion by December. In a parallel strategic move, Tesla's Terafab project is taking shape. The company, alongside SpaceX, plans to build two chip fabrication plants in Austin, Texas—one for vehicles and robots, and another for orbital data centers—with Intel now joining the venture.

Simultaneously, Tesla secured a critical regulatory win in Europe. The Dutch vehicle authority RDW granted the first EU approval for its Full Self-Driving (FSD) Supervised system after 18 months of testing. The company anticipates other EU nations will mutually recognize this Level-2 certification by summer 2026, avoiding full re-testing procedures. This breakthrough coincides with a remarkable sales rebound in key European markets for March. In Germany, new registrations skyrocketed 315% to 9,252 units, Tesla's best March on record, capturing a 13.1% share of the battery-electric vehicle segment. French registrations jumped 203% to 9,569 vehicles, nearing the all-time high from December 2023.

Despite these advances, analysts remain deeply divided. UBS upgraded its rating from "Sell" to "Hold" and raised its price target to $352, but cautioned over weak EV demand, rising costs, and slow progress on the robotaxi network. The firm forecasts only about 1.6 million deliveries for 2026, barely above the prior year. Its projections for the Optimus robot are also conservative, estimating roughly 5,000 units in 2027, rising to 30,000 by 2030—far below Musk's own targets. The dispersion of Wall Street targets is stark, ranging from Wells Fargo's $125 to Wedbush's $600, with Morgan Stanley at $410 and Barclays maintaining a $360 target below the $415 consensus.

The European sales surge offers only partial comfort, as it comes off historically weak year-ago comparables. Furthermore, while the overall European EV market grew 68%, Tesla in France merely held its late-2023 level. The contrast with North America is sharp. U.S. sales in March fell nearly 8% year-over-year to approximately 41,300 vehicles, marking the sixth consecutive monthly decline and putting quarterly results about 12.5% below the prior-year period.

Critical questions about funding and implementation loom. The AI5 chip, promising up to ten times the computing power of its AI4 predecessor, is not destined for the initial Cybercab fleet launching in Q2 2026; those vehicles will use AI4 hardware. Musk stated AI4 is sufficient for driving significantly safer than a human, positioning the AI5 instead for the Optimus robot and supercomputer clusters. A switch to AI5 is not expected until at least mid-2027, when several hundred thousand boards are ready. The chip will be dual-sourced from TSMC in Arizona and Samsung in Texas.

The financial shadow of Terafab is another key concern. The planned domestic semiconductor factory was explicitly not included in Tesla's 2026 capital expenditure guidance of $20 billion. CFO Vaibhav Taneja promised an update in future quarters, leaving analysts like those at Barclays worried about the eventual cost. Prediction markets currently assign a 53% probability that Tesla will miss or merely meet profit expectations. Trading volume on Wednesday hit 113 million shares, about 60% above average, signaling intense market scrutiny.

As the earnings date approaches, the stock trades around €335, still down nearly 10% for the year despite the recent 13% weekly gain. With a Relative Strength Index reading of 70 indicating short-term overbought conditions, all eyes will be on the April 22 report. Investors will demand clarity on automotive gross margins, concrete rollout timelines for commercial robotaxi operations, early economics of the Optimus program, and, crucially, a detailed financial plan for Terafab. The recent rally has raised the stakes, making the upcoming results a pivotal test for Tesla's multifaceted strategy.